

November 4, 2019

**Via EDGAR Transmission**

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Mail Stop 4720  
Washington, D.C. 20549  
Attention: Tonya K. Aldave

**Re: Galera Therapeutics, Inc.  
Registration Statement on Form S-1  
Filed October 11, 2019  
Registration No. 333-234184**

Dear Ms. Aldave:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on November 6, 2019, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Galera Therapeutics, Inc. (the "Company") or its counsel may request via telephone call to the staff. Please contact Nathan Ajiashvili of Latham & Watkins LLP, counsel to the Company, at (212) 906-2916, or in his absence, Peter Handrinos at (617) 948-6060, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

---

Sincerely yours,

**Galera Therapeutics, Inc.**

By: /s/ J. Mel Sorensen

\_\_\_\_\_  
J. Mel Sorensen, M.D.

President and Chief Executive Officer

cc: Nathan Ajiashvili, Esq.  
Peter Handrinos, Esq.